CSTONE PHARMA-B News

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024

May 7 18:08

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE TO PRESENT CS5001 (ROR1 ADC) PHASE I RESULTS AT 2024 ASCO ANNUAL MEETING

May 6 12:00

CSTONE PHARMA-B: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023

Apr 23 17:01

CSTONE PHARMA-B: PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUMAND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEWMEMORANDUM AND ARTICLES OF ASSOCIATION

Apr 15 17:02

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE ACCEPTANCE OF RET INHIBITOR GAVRETO (PRALSETINIB) MANUFACTURING LOCALIZATION APPLICATION BY CENTER FOR DRUG EVALUATION OF CHINA NMPA

Apr 9 08:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024

Apr 5 16:30

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE FIFTH INDICATION APPROVED FOR SUGEMALIMAB IN CHINA AS FIRST-LINE TREATMENT OF GASTRIC CANCER

Mar 15 12:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024

Mar 6 16:30

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT

Mar 4 12:27

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024

Feb 6 19:01

CSTONE PHARMA-B: LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS

Jan 23 17:06

CSTONE PHARMA-B: LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS

Jan 23 17:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023

Jan 5 18:41

CSTONE PHARMA-B: FORM OF PROXY FOR EXTRAORDINARY GENERAL MEETING

Dec 28, 2023 17:09

CSTONE PHARMA-B: INSIDE INFORMATION ANNOUNCEMENT - LATEST BUSINESS UPDATE

Dec 20, 2023 16:30

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES INCLUSION OF AYVAKIT (AVAPRITINIB) IN 2023 CHINA''S NATIONAL REIMBURSEMENT DRUG LIST

Dec 13, 2023 12:09

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES NMPA APPROVAL OF SUGEMALIMAB AS FIRST-LINE TREATMENT FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Dec 8, 2023 12:00

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2023

Dec 6, 2023 16:30

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2023

Nov 6, 2023 16:45

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES STRATEGIC PARTNERSHIP AND EXCLUSIVE LICENSING AGREEMENT WITH 3SBIO FOR NOFAZINLIMAB (ANTI-PD-1 ANTIBODY) IN MAINLAND CHINA

Nov 1, 2023 18:00